MENU

What is Valsartan Acess Program

     The Doh has concluded negotiations and discussion with Novartis Philippines having entered into a Memorandum of Understanding (MOU) dated May 28, 2009 under the MOU, Novartis will grant non-exclusive right to DOH market, promote and sell the Valsartan products under the mark "DOH Valsartan" in all DOH Hospitals and some Local Government Units (LGUs) pharmacies.

     Valsartan provides blood pressure (BP) reductions that last a full 24 hours greater with increasing baseline systolic BP and across diverse patients types and it is available at strengths of Valsartan 80 mg and Valsartan 160 mg film-coated tablets. This anti-hypertensive drug is still under patent until 2014 and has offered 50-60% cheaper compared to the prevailing market price.

     Thirty (30) DOH Retained Hospital and two (2) Provincial Health Offices (PHOs) participated in the first initial orders of Valsartan 80 mg and 160 mg film-coated tablets.